Author Archive: David Thomas, CFA

David Thomas, CFA

David is currently Senior Director of Industry Research and Analysis at BIO in Washington, DC. In this role, he is responsible for financial statistics and analysis of the biotechnology sector and contributes to BIO’s policy activities as well as programming for BIO’s investor conferences. Prior to joining BIO, he was a research scientist at the J. Craig Venter Institute working on the “synthetic cell” team led by Nobel Laureate Hamilton Smith. Before his role in synthetic biology, David worked as a scientist in drug discovery at Amgen, Millennium, and Novartis. His scientific expertise is in protein engineering, enzymology, and synthetic biology. David has earned the Chartered Financial Analyst (CFA) designation and holds a master’s degree in biochemistry.

Latest Posts

Benefiting from Innovative Clinical Trial Designs


Clinical trial success rates have been known to be low for some time now, but that does not imply they will remain low forever. As more tools become available to clinical trial sponsors, technical operators and even patients, future clinical success may look nothing like it has over the last decade. Taking steps to change old fashioned protocols were panelist that gathered for today’s panel on clinical trial innovation trends at the BIO Investor Forum Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Does Big Company M&A Impact Small Company M&A?


Over the last few years, we have seen significant consolidation among the large drug manufacturers, with both franchise swapping and mergers of equals – but what is the impact on small biotechs? At the BIO Investor Forum, (held at the Westin St. Francis in San Francisco today), a panel session moderated by Matthew Hudes, Chief Executive Officer of bdlBiologx, set out to answer that very question. The panelists, all seasoned industry veterans, came from a Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Improving Oncology Clinical Trials

Trial Design

The 18th Annual BIO CEO & Investor Conference kicked off with a panel focused on oncology therapeutics. A group of clinical trial experts gathered Monday morning in New York to discuss how to improve success in drug development. In particular, they explored alternative models for clinical trial design to reach higher success rates. As a lead-in to the challenge faced, preliminary data from BIO and BioMedTracker was presented on clinical development success rates [here, and upcoming data here]. The key takeaway: the most recent decade of data shows oncology Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

2015 FDA Approvals: Highest Levels in Over a Decade


2015 was a blockbuster year for FDA approvals of novel new medicines, many of them for serious and life-threatening conditions. As Dr. John Jenkins of the FDA’s Center for Drug Evaluation and Research (CDER) notes in a recent blog post, “During this past year, we approved many new drugs to treat various forms of cancer, including four to treat multiple myeloma, and others to treat lung, skin, breast, brain, colorectal, and other cancers. We also Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Haves and Have Nots in Biotech Venture Capital


Recent data from the BIO Industry Analysis team tells a story of “haves and have-nots” in US biopharma venture capital. Three key findings were discussed Wednesday at the 14th Annual BIO Investor Forum. The first finding from the recent study is that funding of therapeutic companies is strong for late rounds (Series B and above), but weak for Series A. Although total levels of venture funding have been climbing recently, the majority of the increase is from late rounds. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,